Gilgamesh’s Psychedelic Drug Linked to High Remission Rate in Trial

June 2, 2025

Azurity acquires Arbor Pharmaceuticals to form an integrated entity

September 5, 2021

AstraZeneca Adds Imfinzi and Lynparza to Ovarian Cancer Treatment

June 6, 2023

Must Read

Artios Pharma Raises $115 Million to Advance DDR-Focused Oncology Pipeline

November 21, 2025

CHMP Issues Positive Opinion for Sanofi Teizeild to Delay Progression to Stage 3 Type 1 Diabetes

November 21, 2025

J&J Shells Out $3B to Acquire Halda, Expanding Cancer Portfolio

November 20, 2025

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Merck Gets $700M Funding From Blackstone For Cancer Therapy R&D

Pfizer to Withdraw Vyndaqel in the U.S. Before Patent Expiration in 2028

Roche Ends Development of Obesity Candidate CT-173 and Discontinues Multiple Early-Stage Programs

$20 Million Pediatric CRISPR Center Launched to Develop Treatments for Rare Genetic Diseases

Neurocrine’s Depression Drug Encounters Surprising Phase II Failure

Alixorexton Shows Mixed Efficacy in Mid-Stage Narcolepsy Type 2 Trial

FDA to Remove Broad Black Box Warnings from Menopause Hormone Therapy Labels

Novo Reports Mixed Phase 2 Results for Coramitug in Transthyretin Amyloidosis Cardiomyopathy

Artios Pharma Raises $115 Million to Advance DDR-Focused Oncology Pipeline

Lyell to pay $40M For Colorectal Cancer CAR-T Therapy

Zag Bio Launches with $80 Million Funding to Develop Thymus-Targeted Autoimmune Therapies

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm

Reg impact assessment next in GenAI’s sights, experts claim

The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption

Improving life science R&D outcomes with AI

The medical device sector’s surging regulatory burden: how are suppliers coping?

Insights

Reg impact assessment next in GenAI’s sights, experts claim

The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption

Improving life science R&D outcomes with AI

The medical device sector’s surging regulatory burden: how are suppliers coping?

The Future of Gene Therapies: Three Trends

A Patient Centric Approach to Clinical Research is Key for Product...

Editor Picks

Gilgamesh’s Psychedelic Drug Linked to High Remission Rate in Trial

Azurity acquires Arbor Pharmaceuticals to form an integrated entity

AstraZeneca Adds Imfinzi and Lynparza to Ovarian Cancer Treatment

Must Read

Artios Pharma Raises $115 Million to Advance DDR-Focused Oncology Pipeline

CHMP Issues Positive Opinion for Sanofi Teizeild to Delay Progression to Stage 3 Type 1 Diabetes

J&J Shells Out $3B to Acquire Halda, Expanding Cancer Portfolio

Hot Topics

About Us

Follow Us